WVOS Issues Letter of Concern on Drug Pricing Legislation

On February 23, 2022, the West Virginia Oncology Society (WVOS) issued a letter of concern, urging Senator Joe Manchin to withhold his support of any piece of drug pricing legislation unless providers are removed from the middle of drug pricing negotiations between the federal government and drug manufacturers.

WVOS supports the goal of reducing the cost of prescription drugs for Medicare beneficiaries. However, WVOS is concerned that the maximum fair price standard proposed for achieving cost savings in the Build Back Better Act (BBBA) would negatively impact both cancer care providers who administer drugs covered under Medicare Part B and their patients. 
Read Letter

WVOS Joins Coalition Letter Urging Addition of the Cures 2.0 Concept Paper Title IV Provisions in the Next COVID-19 Relief Package

The West Virginia Oncology Society (WVOS) joined in a coalition letter to congressional leadership urging that Congress include the 21st Century Cures 2.0 concept paper, recently released by Representatives Diana DeGette and Fred Upton in upcoming legislation to further address the COVID-19 public health crisis. Specifically the letter urges leadership to include policy to provide Medicaid coverage of the routine care costs of clinical trials participation for patients with life-threatening conditions in every state. This critical protection is championed by Representatives Ben Ray Luján and Gus Bilirakis in the Clinical Treatment Act (H.R. 913).

• COVID-19 Clinical Trials Coalition Letter